Seamus Fernandez
Stock Analyst at Guggenheim
(4.95)
# 132
Out of 5,023 analysts
416
Total ratings
62.8%
Success rate
28.9%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBX MBX Biosciences | Rated: Buy | $88 → $150 | $58.51 | +156.37% | 16 | Oct 2, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $25 → $26 | $9.14 | +184.46% | 6 | Oct 1, 2026 | |
| IVA Inventiva | Reiterated: Buy | $14 | $3.56 | +293.26% | 8 | Sep 28, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,273 → $1,284 | $1,142.85 | +12.35% | 63 | Sep 17, 2026 | |
| TENX Tenax Therapeutics | Downgraded: Hold | n/a | $1.98 | - | 8 | Aug 31, 2026 | |
| AMLX Amylyx Pharmaceuticals | Rated: Buy | $55 → $57 | $27.79 | +105.11% | 11 | Aug 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $143 | $92.83 | +54.05% | 15 | Aug 24, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $48 → $52 | $23.63 | +120.06% | 9 | Aug 12, 2026 | |
| SEPN Septerna | Reiterated: Buy | $45 → $51 | $37.71 | +35.24% | 3 | Aug 11, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Hold | n/a | $13.03 | - | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 → $38 | $25.16 | +51.03% | 15 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $116 | $56.48 | +105.38% | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $72 → $75 | $61.15 | +22.65% | 50 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 16,500p → 16,200p | 11,870p | +36.48% | 20 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $39.92 | - | 13 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $13.69 | +119.14% | 3 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.39 | +173.35% | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $27.67 | +405.96% | 7 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €110.00 → €101.00 | €70.81 | +42.64% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $37.32 | n/a | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.74 | n/a | 12 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1,779.50 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $47.03 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 → $130 | $144.30 | n/a | 36 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 → $83 | $24.33 | n/a | 5 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.8221 | n/a | 2 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $136.90 | n/a | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $116.34 | n/a | 4 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $141.00 | n/a | 16 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $3.34 | n/a | 1 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.15 | n/a | 2 | Sep 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $37 | $27.80 | n/a | 16 | Sep 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $11.79 | n/a | 1 | Aug 24, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $6.31 | n/a | 3 | Aug 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $219.72 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $403.04 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $735.20 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $256.03 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $56 | $31.80 | n/a | 5 | Jun 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 | $31.65 | n/a | 1 | Mar 7, 2016 |
MBX Biosciences
Oct 2, 2026
Rated: Buy
Price Target: $88 → $150
Current: $58.51
Upside: +156.37%
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $25 → $26
Current: $9.14
Upside: +184.46%
Inventiva
Sep 28, 2026
Reiterated: Buy
Price Target: $14
Current: $3.56
Upside: +293.26%
Eli Lilly and Company
Sep 17, 2026
Reiterated: Buy
Price Target: $1,273 → $1,284
Current: $1,142.85
Upside: +12.35%
Tenax Therapeutics
Aug 31, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.98
Upside: -
Amylyx Pharmaceuticals
Aug 26, 2026
Rated: Buy
Price Target: $55 → $57
Current: $27.79
Upside: +105.11%
Rhythm Pharmaceuticals
Aug 24, 2026
Reiterated: Buy
Price Target: $143
Current: $92.83
Upside: +54.05%
Mineralys Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $48 → $52
Current: $23.63
Upside: +120.06%
Septerna
Aug 11, 2026
Reiterated: Buy
Price Target: $45 → $51
Current: $37.71
Upside: +35.24%
Arcturus Therapeutics Holdings
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $13.03
Upside: -
Aug 5, 2026
Rated: Buy
Price Target: $35 → $38
Current: $25.16
Upside: +51.03%
Aug 5, 2026
Reiterated: Buy
Price Target: $116
Current: $56.48
Upside: +105.38%
Jul 31, 2026
Reiterated: Buy
Price Target: $72 → $75
Current: $61.15
Upside: +22.65%
Jul 9, 2026
Reiterated: Buy
Price Target: 16,500p → 16,200p
Current: 11,870p
Upside: +36.48%
Jul 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $39.92
Upside: -
Jun 24, 2026
Reiterated: Buy
Price Target: $30
Current: $13.69
Upside: +119.14%
May 11, 2026
Reiterated: Buy
Price Target: $12
Current: $4.39
Upside: +173.35%
May 7, 2026
Reiterated: Buy
Price Target: $140
Current: $27.67
Upside: +405.96%
Oct 8, 2025
Reiterated: Buy
Price Target: €110.00 → €101.00
Current: €70.81
Upside: +42.64%
Apr 17, 2025
Downgraded: Hold
Price Target: n/a
Current: $37.32
Upside: n/a
Apr 3, 2025
Rated: Hold
Price Target: n/a
Current: $2.74
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $1,779.50
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $47.03
Upside: n/a
Jan 29, 2024
Reiterated: Buy
Price Target: $125 → $130
Current: $144.30
Upside: n/a
Oct 14, 2022
Reiterated: Buy
Price Target: $250 → $83
Current: $24.33
Upside: n/a
Dec 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.8221
Upside: n/a
Dec 7, 2021
Downgraded: Hold
Price Target: n/a
Current: $136.90
Upside: n/a
Feb 25, 2020
Downgraded: Hold
Price Target: n/a
Current: $116.34
Upside: n/a
Oct 8, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $141.00
Upside: n/a
Oct 17, 2017
Initiated Coverage: Buy
Price Target: $13
Current: $3.34
Upside: n/a
Sep 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.15
Upside: n/a
Sep 8, 2016
Reiterated: Hold
Price Target: $37
Current: $27.80
Upside: n/a
Aug 24, 2016
Reiterated: Buy
Price Target: $108
Current: $11.79
Upside: n/a
Aug 9, 2016
Reiterated: Buy
Price Target: $52
Current: $6.31
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $219.72
Upside: n/a
Jul 15, 2016
Rated: Hold
Price Target: n/a
Current: $403.04
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $735.20
Upside: n/a
Jun 14, 2016
Reiterated: Buy
Price Target: $125
Current: $256.03
Upside: n/a
Jun 13, 2016
Reiterated: Hold
Price Target: $56
Current: $31.80
Upside: n/a
Mar 7, 2016
Downgraded: Hold
Price Target: $4
Current: $31.65
Upside: n/a